{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:49:59Z","timestamp":1787878199563,"version":"build-2784847793"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100007659","name":"Bayer Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,9,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Vardenafil, a potent and selective oral PDE5 inhibitor, is efficacious and generally well-tolerated in men with erectile dysfunction (ED). Of considerable interest to patients and physicians is an understanding of the time required after dosing to attain penile erection sufficient for successful sexual intercourse.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To determine the earliest time to onset of action of vardenafil 10 and 20\u2003mg leading to successful intercourse compared to placebo in men with ED.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A prospective, randomized, double-blind, parallel-group, at-home study of 732 men with ED (mean age 55.5\u2003years) was conducted at 64 sites in North America and Europe. Following a 4-week run-in period, patients were randomized to either vardenafil 10 (N\u2003=\u2003237) or 20\u2003mg (N\u2003=\u2003248) or placebo (N\u2003=\u2003247) to be taken on demand over 4\u2003weeks. Using a stopwatch, patients recorded the elapsed time from dosing to attainment of an erection perceived to be adequate for penetration that led to intercourse completion. Earliest time of onset was defined as the fastest time among the first four doses for each patient. Time points from 25 to 5\u2003minutes were tested for significance (alpha\u2003=\u20030.025) using a backward stepping procedure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Mean baseline erectile function domain score (13.4) indicated moderate ED. Within 25\u2003minutes after dosing, 50%\/53% of men on vardenafil 10\/20\u2003mg had at least one erection in the first four doses perceived to be sufficient for penetration with subsequent intercourse completion compared to 26% on placebo (P\u2003&amp;lt;\u20030.0001). A statistically superior response to vardenafil vs. placebo was observed in these responders at all times \u2265\u200a10 and \u2265\u200a11\u2003minutes (P\u2003&amp;lt;\u20030.025) in the 10 and 20\u2003mg groups, respectively. In a retrospective analysis using time intervals of \u2264\u200a15, \u2264\u200a20, \u2264\u200a25 and \u2264\u200a30\u2003minutes between dosing and erection adequate for penetration, 75\u201377% of these intercourse attempts were successful (SEP3 positive) by patients receiving vardenafil 10\/20\u2003mg, compared to 45\u201347% of attempts by those who received placebo. Vardenafil 10\/20\u2003mg was generally well-tolerated with headache (7%\/12% vs. 1%) and flushing (6%\/9% vs. &amp;lt;\u200a1%) reported more frequently than with placebo. No patient discontinued vardenafil therapy due to adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this large, at-home study, the onset of action of vardenafil with subsequent intercourse completion was recognized as early as 10\u2003minutes after dosing.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/j.1743-6109.2004.04025.x","type":"journal-article","created":{"date-parts":[[2004,9,13]],"date-time":"2004-09-13T09:44:00Z","timestamp":1095068640000},"page":"168-178","source":"Crossref","is-referenced-by-count":47,"title":["Earliest Time to Onset of Action Leading to Successful Intercourse with Vardenafil Determined in an At-Home Setting: A Randomized, Double-Blind, Placebo-Controlled Trial"],"prefix":"10.1093","volume":"1","author":[{"given":"Francesco","family":"Montorsi","sequence":"first","affiliation":[{"name":"Universita Vita Salute San Raffaele , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harin","family":"Padma-Nathan","sequence":"additional","affiliation":[{"name":"The Male Clinic , Beverly Hills, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Buvat","sequence":"additional","affiliation":[{"name":"Centre ETPARP , Lille , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartwig","family":"Schwaibold","sequence":"additional","affiliation":[{"name":"Southmead Hospital, Westbury on Trym , Bristol , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Beneke","sequence":"additional","affiliation":[{"name":"Bayer Vital GmbH , Leverkusen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst","family":"Ulbrich","sequence":"additional","affiliation":[{"name":"Bayer Vital GmbH , Elberfeld , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiemo-Joerg","family":"Bandel","sequence":"additional","affiliation":[{"name":"Bayer HealthCare AG , Hamburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Porst","sequence":"additional","affiliation":[{"name":"Urological Practice , Hamburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2004,9,1]]},"reference":[{"key":"2024032600064025400_bib1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/jama.281.6.537","article-title":"Sexual dysfunction in the United States: Prevalence and predictors","volume":"281","author":"Laumann","year":"1999","journal-title":"JAMA"},{"key":"2024032600064025400_bib2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-5347(17)34871-1","article-title":"Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study","volume":"151","author":"Feldman","year":"1994","journal-title":"J Urol"},{"key":"2024032600064025400_bib3","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/00006842-199807000-00011","article-title":"The relationship between depressive symptoms and male erectile dysfunction: Cross-sectional results from the Massachusetts Male Aging Study","volume":"60","author":"Araujo","year":"1998","journal-title":"Psychosom Med"},{"key":"2024032600064025400_bib4","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1038\/sj.ijir.3900567","article-title":"The worldwide prevalence and epidemiology of erectile dysfunction","volume":"12","author":"McKinlay","year":"2000","journal-title":"Int J Impot Res"},{"key":"2024032600064025400_bib5","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jama.279.17.1333","article-title":"Reports at European Urology Congress reflect issues of interest to aging men","volume":"279","author":"Phillips","year":"1998","journal-title":"JAMA"},{"key":"2024032600064025400_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jama.1993.03510010089036","article-title":"Impotence. NIH consensus development panel on impotence","volume":"270","author":"NIH Consensus Conference.","year":"1993","journal-title":"JAMA"},{"key":"2024032600064025400_bib7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0094-0143(05)70135-X","article-title":"Physician-patient dialogue and clinical evaluation of erectile dysfunction","volume":"28","author":"Chun","year":"2001","journal-title":"Urol Clin North Am"},{"key":"2024032600064025400_bib8","first-page":"48","article-title":"Earliest time of onset of erections with vardenafil determined in an at-home setting","author":"Padma-Nathan","year":"2003","journal-title":"J Androl"},{"key":"2024032600064025400_bib9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1368-5031.2004.00128.x","article-title":"Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction","volume":"58","author":"Stief","year":"2004","journal-title":"Int J Clin Pract"},{"key":"2024032600064025400_bib10","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/j.1939-4640.2002.tb02332.x","article-title":"Vardenafil for treatment of men \u200awith \u200aerectile \u200adysfunction: \u200aEfficacy \u200aand \u200asafety in a randomized, double-blind, placebo-controlled trial","volume":"23","author":"Hellstrom","year":"2002","journal-title":"J Androl"},{"key":"2024032600064025400_bib11","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2337\/diacare.26.3.777","article-title":"Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: A multicenter double-blind placebo-controlled fixed-dose study","volume":"26","author":"Goldstein","year":"2003","journal-title":"Diabetes Care"},{"key":"2024032600064025400_bib12","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1097\/01.ju.0000086947.00547.49","article-title":"Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy","volume":"170","author":"Brock","year":"2003","journal-title":"J Urol"},{"issue":"5 suppl","key":"2024032600064025400_bib13","first-page":"S175","article-title":"Vardenafil exhibits efficacy in men with erectile dysfunction unresponsive to prior sildenafil therapy: Results of a phase III clinical trial\u2014patient response with vardenafil in sildenafil nonresponders (PROVEN)","volume":"15","author":"Carson","year":"2003","journal-title":"Int J Impot Res"},{"key":"2024032600064025400_bib14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s003450000168","article-title":"Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients. A RigiScan and pharmacokinetic study","volume":"19","author":"Klotz","year":"2001","journal-title":"World J Urol"},{"key":"2024032600064025400_bib15","first-page":"204","article-title":"Safety, tolerability and pharmacokinetics of BAY 38-9456 in patients with erectile dysfunction","volume":"163","author":"Sachse","year":"2000","journal-title":"J Urol"},{"key":"2024032600064025400_bib16","first-page":"S103","article-title":"Rapid onset vs. long duration of action: Effect of age and comorbidity on attribute ranking in the men's attitudes to life events and sexuality (MALES) study","volume":"19","author":"Eardley","year":"2004","journal-title":"Sex Relation Ther"},{"key":"2024032600064025400_bib17","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1464-410X.1992.tb15568.x","article-title":"Comparison of effects following the intracorporeal injection of papaverine and prostaglandin E1","volume":"69","author":"Chen","year":"1992","journal-title":"Br J Urol"},{"key":"2024032600064025400_bib18","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/sj.ijir.3900991","article-title":"Tolerability and safety of apomorphine SL (Ixense (TM)","volume":"15","author":"Montorsi","year":"2003","journal-title":"Int J Impot Res"},{"key":"2024032600064025400_bib19","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0090-4295(03)00567-3","article-title":"Minimal time to successful intercourse after sildenafil citrate: Results of a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Padma-Nathan","year":"2003","journal-title":"Urology"},{"key":"2024032600064025400_bib20","first-page":"224","article-title":"Cialis (IC351) provides prompt response and extended period of responsiveness for the treatment of men with erectile dysfunction (ED)","volume":"165","author":"Padma-Nathan","year":"2001","journal-title":"J Urol"},{"key":"2024032600064025400_bib21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000049770","article-title":"Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose","volume":"40","author":"Stark","year":"2001","journal-title":"Eur Urol"},{"issue":"2 suppl","key":"2024032600064025400_bib22","first-page":"31","article-title":"Reliable efficacy over time of vardenafil, a potent, highly selective PDE-5 inhibitor in men with erectile dysfunction: A retrospective analysis of two pivotal phase III studies","volume":"13","author":"Montorsi","year":"2003","journal-title":"Progr\u00e8s en Urologie"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515300771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515300771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/1\/2\/168\/47522131\/jsm_1_2_168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/1\/2\/168\/47522131\/jsm_1_2_168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T01:03:29Z","timestamp":1711415009000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/1\/2\/168\/6863004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9,1]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2004,9,1]]},"published-print":{"date-parts":[[2004,9,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1743-6109.2004.04025.x","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2004,9]]},"published":{"date-parts":[[2004,9,1]]}}}